-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Boston Scientific Corporation Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$9.91 B | $11.89 B | $12.68 B | $14.24 B | $16.75 B |
| Cost of Revenue |
|
$3.51 B | $3.76 B | $4.00 B | $4.35 B | $5.26 B |
| Gross Profit |
|
$6.40 B | $8.13 B | $8.68 B | $9.90 B | $11.49 B |
| Research & Development |
|
$1.14 B | $1.20 B | $1.32 B | $1.41 B | $1.62 B |
| Selling,General & Administrative |
|
$3.79 B | $4.36 B | $4.52 B | $5.19 B | $5.98 B |
| Operating Expense |
|
$5.72 B | $6.30 B | $6.65 B | $7.55 B | $8.89 B |
| Operating Income |
|
$1.04 B | $2.04 B | $1.65 B | $2.34 B | $2.60 B |
| Net Income |
|
-$140.00 M | $1.04 B | $698.00 M | $1.59 B | $1.85 B |
Boston Scientific Corporation Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$1.73 B | $1.93 B | $928.00 M | $865.00 M | $414.00 M |
| Inventories |
|
$1.35 B | $1.61 B | $1.87 B | $2.48 B | $2.81 B |
| Total Current Assets |
|
$6.69 B | $6.32 B | $5.76 B | $6.51 B | $6.92 B |
| Property,Plant and Equipment |
|
$2.54 B | $2.69 B | $2.83 B | $3.30 B | $3.29 B |
| Goodwill |
|
$9.95 B | $11.99 B | $12.92 B | $14.39 B | $17.09 B |
| Total Assets |
|
$30.78 B | $32.23 B | $32.47 B | $35.14 B | $39.40 B |
| Total Liabilities |
|
$15.45 B | $15.61 B | $14.90 B | $15.61 B | $17.39 B |
| Retained Earnings |
|
-$2.38 B | -$1.39 B | -$750.00 M | $819.00 M | $2.67 B |
| Total Shareholder Equity |
|
$15.33 B | $16.62 B | $17.57 B | $19.28 B | $21.77 B |
| Common Stock |
|
$17.00 M | $17.00 M | $17.00 M | $17.00 M | $17.00 M |
Boston Scientific Corporation Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.12 B | $1.09 B | $1.14 B | $1.20 B | $1.27 B |
| Dividends Payout |
|
-$28.00 M | -$55.00 M | -$55.00 M | -$28.00 M | - |
| Capital Expenditures (Capex) |
|
-$376.00 M | -$554.00 M | -$612.00 M | -$800.00 M | -$790.00 M |
| Free Cash Flow (FCF) |
|
$1.13 B | $1.32 B | $914.00 M | $1.70 B | $2.65 B |
Boston Scientific Corporation Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$6.40 B | $8.13 B | $8.68 B | $9.90 B | $11.49 B |
| Gross Profit Margin (%) |
|
64.59% | 68.37% | 68.44% | 69.49% | 68.61% |
| Operating Income |
|
$1.04 B | $2.04 B | $1.65 B | $2.34 B | $2.60 B |
| Operating Income Margin (%) |
|
10.53% | 17.19% | 13.00% | 16.45% | 15.54% |
| Net Income |
|
-$140.00 M | $1.04 B | $698.00 M | $1.59 B | $1.85 B |
| Net Income Margin (%) |
|
-1.41% | 8.76% | 5.50% | 11.19% | 11.06% |
| EBITDA |
|
$1.51 B | $2.52 B | $2.74 B | $3.45 B | $2.60 B |
| EBITDA Margin (%) |
|
15.24% | 21.18% | 21.61% | 24.25% | 15.54% |
Boston Scientific Corporation Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-0.91% | 6.26% | 3.97% | 8.26% | 8.51% |
| Return on Assets (ROA) |
|
-0.45% | 3.23% | 2.15% | 4.53% | 4.70% |
| Debt to Equity |
|
62.24% | 56.85% | 52.82% | 49.23% | 49.36% |
| Debt to total asset |
|
30.99% | 29.32% | 28.59% | 27.02% | 27.28% |
| Enterprise value to revenue |
|
5.93 | 5.72 | 5.88 | 6.50 | 8.47 |
| Enterprise value to EBITDA |
|
38.87 | 26.98 | 27.20 | 26.82 | 54.46 |
| Enterprise value |
|
$58.74 B | $67.95 B | $74.54 B | $92.62 B | $141.77 B |
| Cash to Debt |
|
15.81% | 19.79% | 16.44% | 26.37% | 31.97% |
| Tax Rate (%) |
|
-1.45% | 3.35% | 38.83% | 19.80% | 19.11% |
| Payout Ratio |
|
-20.00% | 5.28% | 7.88% | 1.76% | - |
